Amazon Pharmacy Expands $50 Medicare GLP-1 Access as CVS and Walmart Compete
Amazon, CVS and Walmart are racing to fill a new wave of Medicare weight-loss drug prescriptions after the federal government made certain GLP-1 medications available to eligible beneficiaries for $50 per month.
Amazon Pharmacy is now offering Wegovy, Zepbound KwikPen and Foundayo through the Medicare GLP-1 Bridge, according to Forbes. CMS says the program began July 1 and gives eligible Medicare beneficiaries access to certain GLP-1 drugs while testing how broader coverage could affect Medicare.
The economic consequence is direct. Drugs that have often listed above $1,000 per month are now available to qualifying Medicare patients at a flat $50 monthly copay. Forbes reported that Amazon said the lower price could save customers about $300 million.
Subscribe free for daily political analysis they won’t broadcast. Join 110K+ readers →
The policy consequence is just as important. CMS is using a central processor to handle prior authorization, claims and pharmacy payments, creating a temporary pathway outside normal Part D cost calculations. CMS says the $50 copay does not count toward a beneficiary’s Part D out-of-pocket total.
Public reaction shows high demand but also confusion. Reddit discussions in Medicare and GLP-1 communities have focused on eligibility rules, prior authorization, Extra Help and whether patients will face problems at the pharmacy counter.
The bridge program is scheduled to run through Dec. 31, 2027. That makes the next question bigger than Amazon’s delivery network or CVS and Walmart’s pharmacy reach. The real test is whether Medicare’s temporary obesity-drug access model becomes a lasting federal coverage policy.
Subscribe free for daily political analysis they won’t broadcast. Join 110K+ readers →